PORTLAND, Ore.--
CytoDyn Inc. (“CytoDyn”) (OTC QB: CYDY), a biotechnology company focused
on the development of new therapies for combating infection with immune
deficiency viruses, announced today that it has entered into a research
collaboration with Dr. Bruce Torbett of The Scripps Research Institute
to study CytoDyn's experimental humanized anti-CCR5 antibody PRO 140 in
a pre-exposure prophylaxis (PrEP) model of HIV infection.

The purpose of this study is to assess the potential for the use of PRO
140 to prevent HIV infection. “Published clinical data has demonstrated
that PRO 140 has anti-viral activity. We believe that it is an important
next step for the company to investigate the possibility that PRO 140
might have a role in HIV prevention,” commented Dr. Nader Pourhassan,
CytoDyn’s President and CEO.

“It is well established that CCR5 is an essential co-receptor required
for HIV infection,” said Dr. Richard Trauger, CytoDyn’s Chief Scientific
Officer. “Previously published results from clinical trial subjects have
shown that a single administration of PRO 140 can coat CCR5 positive
cells for up to 45 days, potentially rendering them resistant to HIV
infection. The duration of this effect may allow for an infrequent
dosing regimen suitable for the use of PRO 140 in a preventive setting.
We are excited to initiate this collaboration with Dr. Torbett to
determine, in an animal model of HIV infection, whether administration
of PRO 140 can prevent or significantly diminish a primary HIV
infection.”

The Company

CytoDyn is a biotechnology company focused on developing subcutaneously
delivered humanized cell-specific monoclonal antibodies (mAbs) as entry
inhibitors for the treatment and prevention of HIV and FIV. We currently
have two mAbs under development for HIV infection. PRO 140, recently
acquired from Progenics Pharmaceuticals, is a Late Stage II humanized
mAb with demonstrated antiviral activity in man. PRO 140 blocks the
Human Immunodeficiency Virus (HIV) co-receptor CCR5 without affecting
the normal function of the molecule. Results from Phase I and Phase IIa
human clinical trials have shown that PRO 140 can significantly reduce
viral burden in people infected with HIV. CytoDyn intends to continue to
develop PRO 140 as a therapeutic anti-viral agent in persons infected
with HIV. The second humanized mAb under development is Cytolin, which
targets LFA-1, a membrane associated molecule reported to be important
for entry and fusion of HIV to target cells and for cell-to-cell
transmission. CytoDyn is also exploring the possibility that its
anti-LFA-1 strategy to control HIV infection may be effective to treat
feline immunodeficiency virus (FIV) a retroviral infection in cats, as
well. To test this hypothesis, CytoDyn is developing CytoFeline, a
monoclonal antibody that blocks feline LFA-1. For more information
please go to www.cytodyn.com.

Forward-Looking Statements

This press release includes forward-looking statements and
forward-looking information within the meaning of United States
securities laws. These statements and information represent CytoDyn’s
intentions, plans, expectations and beliefs, and are subject to risks,
uncertainties and other factors, of which many are beyond CytoDyn’s
control. These factors could cause actual results to differ materially
from such forward-looking statements or information. The words
“believe,” “estimate,” “expect,” “intend,” “attempt,” “anticipate,”
“foresee,” “plan,” and similar expressions and variations thereof,
identify certain of such forward-looking statements or forward-looking
information, which speak only as of the date on which they are made.
CytoDyn disclaims any intention or obligation to publicly update or
revise any forward-looking statements or forward-looking information,
whether as a result of new information, future events or otherwise,
except as required by applicable law. Readers are cautioned not to place
undue reliance on these forward-looking statements or forward-looking
information.

While it is impossible to identify or predict all such matters, these
differences may result from, among other things, the inherent
uncertainty of the timing and success of, and expense associated with,
research, development, regulatory approval and commercialization of our
products and product candidates, including the risks that clinical
trials will not commence or proceed as planned; products appearing
promising in early trials will not demonstrate efficacy or safety in
larger-scale trials; future clinical trial data on our products and
product candidates will be unfavorable; our products will not receive
marketing approval from regulators or, if approved, fail to gain
sufficient market acceptance to justify development and
commercialization costs; competing products currently on the market or
in development may reduce the commercial potential of our products;
CytoDyn, our collaborators or others may identify side effects after the
product is on the market; or efficacy or safety concerns regarding
marketed products, whether or not scientifically justified, may lead to
product recalls, withdrawals of marketing approval, reformulation of the
product, additional pre-clinical testing or clinical trials, changes in
labeling of the product, the need for additional marketing applications,
or other adverse events.

We are also subject to additional risks and uncertainties, including
risks associated with the actions of our corporate, academic and other
collaborators and government regulatory agencies; risks from market
forces and trends; potential product liability; intellectual property,
litigation, environmental and other risks; and risks that current and
pending patent protection for our products may be invalid, unenforceable
or challenged, or fail to provide adequate market exclusivity. There are
also substantial risks arising out of our need to raise additional
capital to develop our products and satisfy our financial obligations;
the highly regulated nature of our business, including government
cost-containment initiatives and restrictions on third-party payments
for our products; the highly competitive nature of our industry; and
other factors set forth in our Annual Report on Form 10-K and other
reports filed with the U.S. Securities and Exchange Commission.